DOCSLIB.ORG

Effects of Folinic Acid on Amethopterin-Induced Inhibition of the Ehrlich Ascites Carcinoma ALAN C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Folinic Acid on Amethopterin-Induced Inhibition of the Ehrlich Ascites Carcinoma ALAN C Effects of Folinic Acid on Amethopterin-induced Inhibition of the Ehrlich Ascites Carcinoma ALAN C. SARTORELLI,*HERBERTF. UPCHURCH,ANDBARBARAA. BOOTH* (fiiomedical Division of The Samuel Roberts Noble Foundation, Inc., Ardmore, Oklahoma) SUMMARY The effects of folinic acid on amethopterin-induced inhibition of growth, purine nucleotide biosynthesis, and DNA thymine formation were measured in Ehrlich ascites cells in vivo.Folinic acid prevented the amethopterin-induced prolongation of survival time of tumor-bearing mice at folinic acid levels which caused complete reversal of the inhibition of glycine-2-C14 incorporation into purines by the folie acid antagonist. In contrast, the depression in the rate of conversion of orotic acid-6-C14 to DNA thymine by amethopterin was only partially spared by folinic acid. The prevention of ameth- opterin's inhibitory effects by folinic acid did not appear to be due to prevention of the uptake of drug by ascites cells. The findings are discussed with respect to mechanism of action of the folie acid antagonists. Folinic acid1 has been shown to prevent the relationship. Schrecker et al. (21) recently showed toxicity of folie acid antagonists in rodents (2, 7, that large doses of folinic acid prevented the inhi 10, 17) and to reverse the antineoplastic properties bition of purine biosynthesis by folie acid antago of this class of antimetabolites (4, 8, 9, 16). nists in leukemic spleens of L1210-bearing mice. Furthermore, the growth inhibition caused by Since the biosynthesis of DNA thymine is also amethopterin in cultured mammalian cell lines markedly inhibited by folie acid antagonists, it was found to be competitively reversed by folinic was of interest to compare the effects of folinic acid (1, 11). Since folinic acid is a tetrahydrofolic acid on the amethopterin-induced inhibition of acid derivative, this appeared to suggest that a the biosynthesis of polynucleotide purines and reaction(s) in addition to the reduction of folie DNA thymine. The results indicated that com acid is inhibited by the folie acid antagonists. plete prevention of the inhibition of purine forma Amethopterin-induced inhibition of formate-C14 tion was obtained at levels of folinic acid which incorporation into nucleic acid purines was shown only partially prevented the drug-induced inhibi by Skipper et al. (22) to be partially reversed by tion of DNA thymine synthesis. folie acid. In rabbit bone marrow, folinic acid partially prevented the reduction of formate-C14 MATERIALS AND METHODS incorporation into DNA brought about by aminop- Experiments were performed on 6- to 11-week- terin, whereas folie acid was ineffective (23). old female Ha/ICR Swiss mice purchased from Winzler et al. (25), employing suspensions of leu- the A. R. Schmidt Co., Madison, Wis. Tumor kemic leukocytes, found that relatively high con transplantation was carried out by aseptically centrations of folinic acid were more effective than withdrawing ascites fluid from a donor mouse was folie acid in reversing the inhibition of formate bearing a 7-day Ehrlich ascites tumor growth. incorporation into these cells by amethopterin. The fluid was centrifuged for 2 minutes in a clinical The manner of reversal suggested a competitive centrifuge (1600 X g), supernatant peritoneal fluid was decanted, a 10 X dilution with isotonic saline * Present address: Department of Pharmacology, Yale was made, and 0.1 ml. (approximately 2 X IO6 University School of Medicine, New Haven, Connecticut. 1The following abbreviations are used: folinic acid, N5- ascites cells) of the cell suspension was inoculated formyltetrahydrofolic acid; DNA, deoxyribonucleic acid; NA, intraperitoneally into each animal. In all experi nucleic acid; AS, acid-soluble. ments, mice were maintained on Rockland rat Received for publication August 11, 1961. chow pellets and water ad libitum. 102 Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 1962 American Association for Cancer Research. SARTORELLIetal.—Effectsof Folinic Acid 103 Survival experiments.—Mice were distributed tion of survival time of mice bearing the Ehrlich into groups of comparable weight, and therapy ascites carcinoma. Folinic acid by itself did not was begun 24 hours after tumor implantation. affect survival; however, concentrations of folinic Treatments were continued once daily for 6 con acid from 1.25-10 ing/kg body weight completely secutive days. Drugs were administered in vol prevented the tumor inhibition produced by 0.5 umes of 0.25-0.5 ml. In each experiment, tumor- mg/kg of amethopterin. bearing animals receiving injections of a compa The effects of folinic acid and amethopterin on rable volume of vehicle were included to serve as purine biosynthesis de novo were measured, and controls. Animals were weighed during treatment, the results obtained are shown in Table 2. Gly- and excessive weight loss was used as an indica cine-2-C14 incorporation into polynucleotide and tion of drug toxicity. The survival time of groups acid-soluble adenine was used as the measure of of tumor-bearing animals was used as the criterion purine formation. Folinic acid at 5 mg/kg had no of tumor inhibition. effect on purine synthesis but at 10 mg/kg caused Biocliemical experiments.—Amethopterin and a slight stimulation of glycine incorporation. folinic acid (Lederle Div., American Cyanamid Amethopterin treatment produced approximately Co., New York, N. Y.) were dissolved in isotonic 75 per cent retardation of uptake of isotopie pre sodium bicarbonate and injected intraperitoneally cursor. Increasing doses of folinic acid caused a into mice bearing a 6-day ascitic growth. At continuous lessening of amethopterin-induced in various times after these injections, each mouse hibition: at a folinic acid concentration of 2.5 mg/ received an intraperitoneal injection either of 100 kg, amethopterin produced 35 per cent inhibition; fig. of glycine-2-C14 (Tracerlab, Inc., Waltham, at 5 mg/kg of folinic acid, 15 per cent inhibition Mass.) (IO4counts/min/^ug) or of 100 fig. of orotic was observed; and 10 mg/kg of folinic acid com acid-6-C14 (Yolk Radiochemical Co., Chicago, 111.) pletely reversed the amethopterin-induced retar (1.7 X IO4 counts/min/Mg). One hour later the dation of purine synthesis. desired metabolites were isolated, and their spe An identical series of experiments was per cific radioactivities were determined as described formed measuring the effects of these agents on in the previous report (20). The folinic acid used the formation of DNA thymine. Orotic acid-6-C14 in these experiments was the calcium salt of the incorporation into DNA thymine was employed synthetic product and contained the inactive op as a measure of this metabolic route. The results tical isomer. Therefore, the concentrations spec obtained are presented in Table 3. Folinic acid had ified in the text are one-half the effective concen little effect on the rate of incorporation of labeled tration. orotic acid into DNA thymine but caused some RESULTS prevention of the inhibition produced by amethop Table 1 presents the effects of various doses of terin. The degree of reversal of amethopterin folinic acid on the amethopterin-induced prolonga inhibition was relatively insensitive to increasing TABLE1 EFFECTOFFOI.INICACJDONTHETUMOR-INHIBITOBYPROPERTIESOFAMETHOPTERIN A TreatmentControlFolinic dosage survival(days)10.5 «rt.(gm.)*+0.7+0.2 (mg/kg)2.5 +0.89.0 acidAmethopterinAmethopterin+folinic + 0.7 50.50.5+1.25 12.«±1.019.7 +2.4—1.1—0.8+2.2 +1.87.8 acidDaily + 1.3 0.5+2-5 8.9 + 1.2 0.5+5 7.5±0.6 +0.4+2.5 0.5+10Average 10.2 + 1.2Av. Drugs were administered intraperitoneally once daily for 6 consecutive days, beginning 24 hours after tumor implantation, with combination treatments given simultaneously. Controls are tumor-bearing animals given injections of isotonic sodium bicarbonate. Each figure represents the average ±standard error of results from ten to fifteen animals. * Average weight change from onset to termination of drug treatment. Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 1962 American Association for Cancer Research. 104 Cancer Research Vol. 22, January 1962 concentrations of folinic acid. Furthermore, com bition of purine biosynthesis as did the simulta plete prevention of inhibition was not observed at neous administration of these two agents (Table doses of folinic acid up to 20 mg/kg. 5). Since folinic acid had been found to suppress the uptake of aminopterin by microbial cells (18, DISCUSSION 26), it was of interest to estimate the possible role Folinic acid itself is not the formyl donor in the of this phenomenon in the reversal of inhibition biosynthesis of purine and thymine nucleotides observed in the present study. The data presented but requires conversion to N'°-formyltetrahydro- in Table 4 indicate that folinic acid administered folic acid and to N6, N10-methenyltetrahydrofolic 30 minutes prior to or 30 minutes after the dose of acid to supply the cofactors required in the bio amethopterin completely reversed the growth in synthesis of purine nucleotides, and presumably a hibition by amethopterin. Furthermore, folinic conversion to N5, N10-methylenetetrahydrofolic to acid administered 30 minutes after a dose of 0.5 supply the one-carbon unit of thymidylic acid mg/kg of amethopterin brought about the same formation (3, 12, 19). The finding that folinic degree of reversal of amethopterin-induced inhi acid, at levels up to 20 mg/kg body weight, only TABLE2 EFFECTOFFOLINICACIDONTHEINCORPORATIONOFGLYCiNE-2-C"INTOADEMNEOFEHRLICHASCITESCELLS cent X cent X10-»NA 10-! AS TreatmentControlFolinic (mg/kg)5 of contro) of control adenine3.1+0.33.3±0.6 value106 adenine79.8 value105 3.984.1+8.0+ acidAmethopterinAmethopterin+folinic 100.50.5+2.5 4.4±0.30.7±0.42.0±0.31422365 100.56.918.8±6.050.9+ 1262464 acidDosage + 6.6 0.5+5 2.6 + 0.2 84 68.6 + 6.8 86 0.5+10Counts/min/Mmole3.6 + 0.7Per 116Counts/min/Mmole80.8 + 5.1Per 101 Tumor-bearing mice were each treated by intraperitoneal injection with the indicated dosage of amethopterin, folinic acid, or the simultaneous combination of amethopterin and folinic acid.
Load more

Recommended publications
  • Methionine Synthase Supports Tumor Tetrahydrofolate Pools
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284521; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Methionine synthase supports tumor tetrahydrofolate pools Joshua Z. Wang1,2,#, Jonathan M. Ghergurovich1,3,#, Lifeng Yang1,2, and Joshua D. Rabinowitz1,2,* 1 Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey, USA 2 Department of Chemistry, Princeton University, Princeton, New Jersey, USA 3 Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA # These authors contributed equally to this work. *Corresponding author: Joshua Rabinowitz Department of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Washington Rd, Princeton, NJ 08544, USA Phone: (609) 258-8985; e-mail: [email protected] Conflict of Interest Disclosure: J.D.R. is a paid advisor and stockholder in Kadmon Pharmaceuticals, L.E.A.F. Pharmaceuticals, and Rafael Pharmaceuticals; a paid consultant of Pfizer; a founder, director, and stockholder of Farber Partners and Serien Therapeutics. JDR and JMG are inventors of patents in the area of folate metabolism held by Princeton University. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284521; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Mammalian cells require activated folates to generate nucleotides for growth and division. The most abundant circulating folate species is 5-methyl tetrahydrofolate (5-methyl- THF), which is used to synthesize methionine from homocysteine via the cobalamin-dependent enzyme methionine synthase (MTR).
    [Show full text]
  • L-Carnitine, Mecobalamin and Folic Acid Tablets) TRINERVE-LC
    For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only (L-Carnitine, Mecobalamin and Folic acid Tablets) TRINERVE-LC 1. Name of the medicinal product Trinerve-LC Tablets 2. Qualitative and quantitative composition Each film- coated tablets contains L-Carnitine…………………….500 mg Mecobalamin……………….1500 mcg Folic acid IP…………………..1.5mg 3. Pharmaceutical form Film- coated tablets 4. Clinical particulars 4.1 Therapeutic indications Vitamin and micronutrient supplementation in the management of chronic disease. 4.2 Posology and method of administration For oral administration only. One tablet daily or as directed by physician. 4.3 Contraindications Hypersensitivity to any constituent of the product. 4.4 Special warnings and precautions for use L-Carnitine The safety and efficacy of oral L-Carnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral L-Carnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine. Mecobalamin Should be given with caution in patients suffering from folate deficiency. The following warnings and precautions suggested with parent form – vitamin B12 The treatment of vitamin B12 deficiency can unmask the symptoms of polycythemia vera. Megaloblastic anemia is sometimes corrected by treatment with vitamin B12. But this can have very serious side effects. Don’t attempt vitamin B12 therapy without close supervision by healthcare provider. Do not take vitamin B12 if Leber’s disease, a hereditary eye disease.
    [Show full text]
  • Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analogues
    Published OnlineFirst September 8, 2009; DOI: 10.1158/0008-5472.CAN-09-1927 Experimental Therapeutics, Molecular Targets, and Chemical Biology Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analogues Dong Wu,1 Yang Li,1 Gaojie Song,1 Chongyun Cheng,1 Rongguang Zhang,2 Andrzej Joachimiak,2 NeilShaw, 1 and Zhi-Jie Liu1 1National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China and 2Structural Biology Center, Argonne National Laboratory, Argonne, Illinois Abstract of the one-carbon metabolic network, dihydrofolate reductase, 5,10-Methenyltetrahydrofolate synthetase (MTHFS) regulates which catalyzes the conversion of dihydrofolate to tetrahydrofolate. the flow of carbon through the one-carbon metabolic network, Similarly, colorectal and pancreatic cancers are routinely treated by which supplies essential components for the growth and administration of the pyrimidine analogue 5-fluorouracil (5-FU), proliferation of cells. Inhibition of MTHFS in human MCF-7 which inhibits thymidylate synthase (TS; ref. 6). TS converts breast cancer cells has been shown to arrest the growth of deoxyuridylate to deoxythymidylate using a carbon donated by cells. Absence of the three-dimensional structure of human 5,10-methylenetetrahydrofolate (Fig. 1). This conversion is essential MTHFS (hMTHFS) has hampered the rational design and for DNA synthesis (7). To increase the clinical efficiency of the optimization of drug candidates. Here, we report the treatment, 5-formyltetrahydrofolate is often coadministered along structures of native hMTHFS, a binary complex of hMTHFS with 5-FU. The beneficial effect of administering 5-formyltetrahy- with ADP, hMTHFS bound with the N5-iminium phosphate drofolate during the therapy with 5-FU is a consequence of the reaction intermediate, and an enzyme-product complex of 5,10-methenyltetrahydrofolate synthetase (MTHFS)–catalyzed hMTHFS.
    [Show full text]
  • Considerations for Crop Biofortification
    fpls-09-00443 April 4, 2018 Time: 16:15 # 1 REVIEW published: 06 April 2018 doi: 10.3389/fpls.2018.00443 Toward Eradication of B-Vitamin Deficiencies: Considerations for Crop Biofortification Simon Strobbe and Dominique Van Der Straeten* Laboratory of Functional Plant Biology, Department of Biology, Ghent University, Ghent, Belgium ‘Hidden hunger’ involves insufficient intake of micronutrients and is estimated to affect over two billion people on a global scale. Malnutrition of vitamins and minerals is known to cause an alarming number of casualties, even in the developed world. Many staple crops, although serving as the main dietary component for large population groups, deliver inadequate amounts of micronutrients. Biofortification, the augmentation of natural micronutrient levels in crop products through breeding or genetic engineering, is a pivotal tool in the fight against micronutrient malnutrition (MNM). Although these approaches have shown to be successful in several species, a more extensive knowledge of plant metabolism and function of these micronutrients is required to refine and improve biofortification strategies. This review focuses on the relevant B-vitamins Edited by: (B1, B6, and B9). First, the role of these vitamins in plant physiology is elaborated, Alexander Arthur Theodore Johnson, as well their biosynthesis. Second, the rationale behind vitamin biofortification is University of Melbourne, Australia illustrated in view of pathophysiology and epidemiology of the deficiency. Furthermore, Reviewed by: advances in biofortification, via metabolic engineering or breeding, are presented. Finally, Francesco Di Gioia, University of Florida, United States considerations on B-vitamin multi-biofortified crops are raised, comprising the possible Aymeric Goyer, interplay of these vitamins in planta.
    [Show full text]
  • Recombinant Human Dihydrofolate Reductase/DHFR
    Recombinant Human Dihydrofolate Reductase/DHFR Catalog Number: 8456-DR DESCRIPTION Source E. coli­derived Met1­Asp187, with a C­terminal 6­His tag Accession # P00374 N­terminal Sequence Met1 & Val2 Analysis Predicted Molecular 22 kDa Mass SPECIFICATIONS SDS­PAGE 23 kDa, reducing conditions Activity Measured by the reduction of dihydrofolic acid (DHF). The specific activity is >5,500 pmol/min/μg, as measured under the described conditions. Endotoxin Level <1.0 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS­PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane. Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, Glycerol, Brij­35 and DTT. See Certificate of Analysis for details. Activity Assay Protocol Materials l Assay Buffer: 50 mM MES, 25 mM Tris, 100 mM NaCl, 25 mM Ethanolamine, 2 mM DTT l Recombinant Dihydrofolate Reductase/DHFR (rhDHFR) (Catalog # 8456­DR) l β­Nicotinamide adenine dinucleotide phosphate reduced, tetrasodium salt (β­NADPH) (Sigma, Catalog # N7505), 10 mM stock in deionized water l Dihydrofolic acid (DHF) (Sigma, Catalog # D7006), 10 mM stock in Assay Buffer + 4.5 mM NaOH l 96­well Clear Plate (Catalog # DY990) l Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent Assay 1. Dilute rhDHFR to 1 μg/mL in Assay Buffer. 2. Prepare a Substrate Mixture containing 0.2 mM DHF and 0.25 mM β­NADPH in Assay Buffer. 3. Load 50 μL of 1 μg/mL rhDHFR into a plate, and start the reaction by adding 50 μL of Substrate Mixture.
    [Show full text]
  • Oral Immunosuppressive Drugs in the Treatment of Atopic Dermatitis
    Oral immunosuppressive drugs in the treatment of atopic dermatitis IMPROVING PERFORMANCE AND SAFETY FLOOR M. GARRITSEN Colofon Oral immunosuppressive drugs in the treatment of atopic dermatitis Improving performance and safety Thesis with a summary in Dutch, Utrecht University, the Netherlands © Floor Garritsen, 2018 No part of this thesis may be reproduced, stored or transmitted, in any form or by any means, without prior permission of the author. ISBN: 978-90-393-6931-9 Cover design and layout: Die Jongens Printed and published by: Proefschriftmaken.nl Oral immunosuppressive drugs in the treatment of atopic dermatitis: improving performance and safety Orale immunosuppressiva bij de behandeling van constitutioneel eczeem: het verbeteren van effectiviteit en veiligheid (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof. dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op donderdag 8 februari 2018 des middags te 2.30 uur door Floralie Maria Garritsen geboren op 22 oktober 1986 te Beek en Donk Promotor: Prof. dr. C.A.F.M. Bruijnzeel-Koomen Copromotoren: Dr. M.S. de Bruin-Weller Dr. M.P.H. van den Broek Table of contents Chapter 1 General introduction 7 Part I – Qualitative and quantitative exploration of oral immunosuppressive drug use in the Netherlands Chapter 2 Ten years experience with oral immunosuppressive treatment 23 in adult patients with atopic dermatitis in two
    [Show full text]
  • BIOPAR DELTA-FORTE- 1 Nf Units, 50 Mcg Cbl, 2.5 Mg F-Thf, 1
    BIOPAR DELTA-FORTE- 1 nf units, 50 mcg cbl, 2.5 mg f-thf, 1 mg pteglu-, 7 mg me- thf capsule Jaymac Pharmacueticals LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- BioparTM delta-FORTE DESCRIPTION [1 NF Units] [50 mcg CBl] [2.5 mg F-THf] [1 mg PteGlu-] [7 mg Me-THf] Prescription Hematopoietic Preparation For Therapeutic Use Multiphasic Softgels (30ct carton) NDC 64661-793-30 Rx ONLY BioparTMdelta-FORTE is an orally administered prescription hematopoietic preparation for therapeutic use formulated for adult macrocytic anemia patients – specifically including pernicious anemia patients, ages 12 and up, who are under specific direction and monitoring of cobalamin and folate status by a physician. A recent study+ suggested that BioparTM delta-FORTE was effective in lowering homocysteine levels in patients that are positive for MTHFR (methylenetetrahydrofolate reductase polymorphism). BioparTM delta-FORTE may be taken by women of childbearing age. BioparTM delta- FORTE may be taken by geriatric patients where compliance is an issue. + ClinicalTrials.gov identifier: NCT02709668, Correlation of Clinical Response With Homocysteine Reduction During Therapy With Reduced B Vitamins in Patients with MDD Who Are Positive for MTHFR C677T or A1298C Polymorphism. INGREDIENTS Cobalamin-intrinsic factor concentrate (non-inhibitory)1 .............................................................................................
    [Show full text]
  • GRAS Notice 915, Calcium L-Methylfolate
    GRAS Notice (GRN) No. 915 https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory Form Approved: 0MB No. 0910-0342; Expiration Date: 09/30/2019 (See last naae for 0MB Statement) FDA USE ONLY , 'GRN NUM~ER QATE OF. RECEIF!T DEPARTMENT OF HEALTH AND HUMAN SERVICES -- - ESTIMATED DAlllY·INTAKE fNTENDED USE FQ~ INTERNET Food and Drug Administration Ii .. GENERALLY RECOGNIZED AS SAFE -- 'NAME F:OR INTERNET (GRAS) NOTICE (Subpart E of Part 170) - - ,~ Y.WORDS I l I ~ .. Transmit completed form and attachments electronically via the Electronic Submission Gateway (see Instructions); OR Transmit completed form and attachments in paper format or on physical media to: Office of Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration,5001 Campus Drive, College Park, MD 20740-3835. SECTION A- INTRODUCTORY INFORMATION ABOUT THE SUBMISSION 1. Type of Submission (Check one) ~ New D Amendment to GRN No. D Supplement to GRN No. 2. [gl All electronic files included in this submission have been checked and found to be virus free. (Check box to verify) 3 Mosl recent presuom1ss1on meeung (" any) w1m FDA on the subject substance (yyyylmmldd): 12/17/2018 4 For Amendments or Supplements: Is your (Check one) amendment or supplement submitted in D Yes If yes, enter the date of response lo a communication from FDA? D No communication (yyyy/mmldd): ______ SECTION B - INFORMATION ABOUT THE NOTIFIER Name of Contact Person Position or Title William Turney Head of Regulatory Affairs NA Organization (if applicable) 1 a. Notifier DSM Nutritional Products Mailing Address (number and street) 45 Waterview Blvd.
    [Show full text]
  • The Changing Faces of Vitamin B12 and Folic Acid – Part Two: Integration of Symptoms, and Genetic Testing to Select the Best Drugs for Your Patient
    The Changing Faces of Vitamin B12 and Folic Acid – Part two: Integration of symptoms, and genetic testing to select the best drugs for your patient By: Dan Carter, ND The symptoms of vitamin B12 deficiency range from mild to severe, and in many cases are not specific enough to confirm a diagnosis. Symptoms can include diarrhea or constipation, fatigue, light headedness on standing, poor appetite, pallor, difficulty concentrating, shortness of breath on exertion, glossitis. Neurologic symptoms can appear after chronic deficiency and involve changes in mental status, depression, peripheral neuropathy, loss of balance. [Anemia – B12 deficiency. http://www.nlm.nih.gov/medlineplus/ency/article/000574.htm] Some of the symptoms of folate deficiency overlap with B12, including fatigue and glossitis, but others such as accelerated graying of hair, oral ulcers, and poor growth rates do not. [Folate deficiency. http://www.nlm.nih.gov/medlineplus/ency/article/000354.htm] The indicated blood tests for B12 deficiency are complete blood count (CBC), reticulocyte count, serum LDH and vitamin B12, while those for folate deficiency are CBC, serum and RBC folate. Other useful tests are serum homocysteine and methylmalonic acid (MMA). Serum homocysteine will be high with both deficiencies, while only MMA will be increased in B12 deficiency. [Vitamin B12 and Folate. http://labtestsonline.org/understanding/analytes/vitamin-b12/tab/test] As genetic testing has become more widely available, specific analysis of known single nucleotide polymorphisms (SNP) is increasingly accepted as an aid to diagnosis. In the case of folate metabolism several SNP have been identified as significant; the first SNP to gain widespread attention affected the MTHFR gene.
    [Show full text]
  • Simulation of Food Folate Digestion and Bioavailability of an Oxidation Product of 5-Methyltetrahydrofolate
    Article Simulation of Food Folate Digestion and Bioavailability of an Oxidation Product of 5-Methyltetrahydrofolate Christiane Ringling 1 and Michael Rychlik 1,2,* 1 Division BIOANALYTIK Weihenstephan, Research Center for Nutrition and Food Sciences (Z. I. E. L.), Technical University of Munich, Alte Akademie 10, D-85350 Freising, Germany; [email protected] 2 Chair of Analytical Food Chemistry, Technical University of Munich, Alte Akademie 10, D-85350 Freising, Germany * Correspondence: [email protected]; Tel.: +49-8161-71-3746; Fax: +49-8161-71-4216 Received: 22 July 2017; Accepted: 28 August 2017; Published: 1 September 2017 Abstract: Generating bioavailability data from in vivo studies is time-consuming and expensive. In vitro simulation can help to investigate factors influencing bioavailability or facilitate quantifying the impact of such factors. For folates, an efficient deconjugation of polyglutamates to the corresponding monoglutamates is crucial for bioavailability and highly dependent on the food matrix. Therefore, the bioaccessibility of folates of different foodstuffs was examined using a simulated digestion model with respect to folate stability and the efficiency of deconjugation. For realistic simulated deconjugation, porcine brush border membrane was used during the phase of the simulated digestion in the small intestine. For a better understanding of folate behaviour during digestion, single folate monoglutamates were also investigated with this in vitro digestion model. The results for bioaccessibility were compared with data from a human bioavailability study. They support the idea that both stability and deconjugation have an influence on bioaccessibility and thus on bioavailability. Tetrahydrofolate is probably lost completely or at least to a high extent and the stability of 5-methyltetrahydrofolate depends on the food matrix.
    [Show full text]
  • Produktinformation Todavit
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT TODAVİT powder for solution for I.M./I.V. injection/ infusion Sterile 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: In each vial; Vitamin A (as Retinol palmitate) 3500 IU (2,06 mg) Vitamin D3 (Cholecalciferol) (made from sheep wool.) 220 IU (0,22 mg) Vitamin E (11,2 mg Vitamin E as acetate) 11,2 IU Vitamin C (Ascorbic acid ) 125 mg Vitamin B1 (Thiamine; 3,935 mg asThiamine HCl) 3,51 mg Vitamin B2 (Riboflavin; 5,26 mg Riboflavin sodium phosphate) 4,14 mg Vitamin B6 (Piridoxin; 5,5 mg as Piridoxin hydrochloride) 4,53 mg Vitamin B12 (Cyanocobalamin) 0,006 mg Folik acid 0,414 mg Pantothenic acid (16,15 mg asDexpanthenol) 17,25 mg D-Biotin 0,069 mg Nicotinamide 46 mg Excipients: Sodium hydroxide: q.s. Soy lecithin: 112.5 mg For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Yellow-orange colored lyophilized cake. Sterile. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications In accordance with the daily needs of adults and children over 11 years of age,it is indicated when oral intake is contraindicated or inadequate (malnutrition, gastrointestinal malabsorption, parenteral nutrition, etc.) or when it is not possible, intravenously. 1/15 4.2. Posology and method of administration Posology / Application frequency and duration: In adults and children over 11 years old, the daily dose is 1 vial. In special cases with increased nutritional requirements (severe burns, etc.), high doses such as 2-3 vials daily can be used. Method of Application: It is used intravenously or intramuscularly.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0035087 A1 Barclay (43) Pub
    US 20020035087A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0035087 A1 Barclay (43) Pub. Date: Mar. 21, 2002 (54) B COMPLEX VITAMIN COMPOSITIONS (57) ABSTRACT THAT PROTECT AGAINST CELLULAR The present invention relates generally to the use of Vitamin DAMAGE CAUSED BY ULTRAVIOLET B12 (cobalamin or cyanocobalamin) alone or in combina LIGHT tion with other photoprotective agents, including Specifically other vitamins such as vitamin B9 (folic acid or folate) and Vitamin B3 (niacin or niacinamide), or any chemical deriva (76) Inventor: Barry J. Barclay, St. Albert (CA) tive of these Vitamins and their Salts, as a filter to protect cells against the damaging effects of ultraviolet (UV) light. The invention is, in one aspect, a method of reducing the rate Correspondence Address: of UV damage to cells exposed to a UV light source, by Kevin S. Lemack treating the celis with the Vitamin composition, either alone Nields & Lemack or in combination with other photoprotective agents. Other 176 E. Main Street - Suite 8 aspects of the invention are compositions comprising effec Westboro, MA 01581 (US) tive amounts of vitamin B12 alone or in combination with other photoprotective agents including Vitamin B9 and Vita min B3 and a pharmaceutically-acceptable carrier, that are (21) Appl. No.: 09/900,064 useful in protecting cells, particularly Skin cells, against the burning, genotoxic (mutagenic and carcinogenic), immuno (22) Filed: Jul. 6, 2001 Suppressive and photoaging effects of UV light, especially Sunlight. The invention has application as a UV light filter in (30) Foreign Application Priority Data oral preparations including tablets and drinks, topical creams, lotions, sprays, wipes and cosmetics.
    [Show full text]